Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors

This phase 1 postapproval study assessed the effect of the mitogen‐activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined oral contraceptives (COCs) containing norethindrone (NE; 1 mg daily) and ethinyl estradiol (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Arkenau, Hendrik‐Tobias, Taylor, Donatienne, Xu, Xiaoying, Chitnis, Shripad, Llacer‐Perez, Casilda, Moore, Kathleen, Nidamarthy, Prasanna Kumar, Ilankumaran, Palanichamy, De Vos‐Geelen, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304124/
https://www.ncbi.nlm.nih.gov/pubmed/35157784
http://dx.doi.org/10.1002/cpdd.1052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304124/
https://www.ncbi.nlm.nih.gov/pubmed/35157784
http://dx.doi.org/10.1002/cpdd.1052

Ejemplares similares